Džubák Petr M.D., Ph.D.
E-mail:
petr.dzubak@upol.cz
Telefon:
+420 585632150, +420 604851158
Skupiny:
ÚMTM, LEM, PERSONÁL, VEDOUCÍ
O mně
Scientist and pediatrician involved in molecular and translational medicine (disease area oncology and infectious diseases), leader of research program Chemical Biology and Experimental Therapeutics at IMTM. Actively participated in the research of more than 20 national and international projects; member of advisory board of Cancer Research Foundation „Rakovina ve veřejná“, co-founder of spin-off company focused on manufacturing of molecular diagnostics. Published more than >140 papers and books/chapters, >3552 SCI citations, H-index 27, Prix de Pharmacie 2007 Ambassade de France – Sanofi-aventis, Premier Prix.
Specialties: Molecular and translational medicine, Oncology, Drug research and development, MOA, Drug resistance
Journals
Anticancer 5-arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones as tubulin inhibitors.
Archiv der Pharmazie.
2022,
355(12),
e2200419,
ISSN: 0365-6233,
PMID: 36109178,
Intellectual property
METHOD OF DIAGNOSIS AND/OR PROGNOSIS AND/OR PREDICTION OF THERAPEUTIC RESPONSE OF NEOPLASTIC DISEASES (Varanasi)
- Published Application EP 16153221.3 under EP 3199949 (2.8.2017)
- Published Application PCT/CZ2017/050003 under WO 2017/129154 (3.8.2017)
Status: Terminated
15BETA-SUBSTITUTED ESTRONE DERIVATIVES AS SELECTIVE INHIBITORS OF 17BETA-HYDROXYSTEOID-DEHYDROGENASES, METHOD OF PREPARATION AND USE THEREOF (Kotora)
- Patent: CZ 307437. Granted: 11.7.2018. Ownership: Institute of Organic Chemistry and Biochemistry AS CR, Helmholtz Zentrum Munchen GmbH, Institute of Molecular Genetics, Palacký University, Olomouc, Inventors: Kotora Martin, Prchalová Eva, Adamski Jerzy, Moller Gabriele, Štěpánek Ondřej, Bartůněk Petr, Sedlák David, Džubák Petr, Hajdúch Marián
- Published Application PCT/CZ2017/050010 under WO 2017/148455 (8.9.2017)
- Published Application EP 17731057.0 under EP 3464314 (10.4.2019)
- Published Application AU 2017/276477 under AU 2017276477 (29.11.2018)
- Published Application CA 3.026.704 under CA 3026704 (14.12.2017)
- Published Application US 2017/16305829 under US 2019330258 (31.10.2019)
Status: Terminated
SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE (Hocek)
- Published Application PCT/CZ2016/050021 under WO 2018/001393 (4.1.2018)
- Patent: EP 3478701; Granted: 10.8.2022; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Prague; Palacký University, Olomouc; Inventors: Hocek Michal, Tichý Michal, Hajdúch Marián, Džubák Petr
- Patent: US 10,414,788; Granted: 17.9.2019; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Prague; Palacký University, Olomouc; Inventors: Hocek Michal, Tichý Michal, Hajdúch Marián, Džubák Petr
- Patent: JP 6650074; Granted: 21.1.2020; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Prague; Palacký University, Olomouc; Inventors: Hocek Michal, Tichý Michal, Hajdúch Marián, Džubák Petr
- Patent: CA 3.029.170; Granted: 16.2.2021; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University, Olomouc; Inventors: Hocek Michal, Tichý Michal, Hajdúch Marián, Džubák Petr
Status: Terminated
Open positions
| Projekt: | Identification of proteomic biomarkers in exhaled air condensate in patients with systemic or pulmonary disease |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Souhrn: | 2 places in full-time study |
| Projekt: | Antitumor drugs targeting nucleic acid metabolism |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Souhrn: | 2 places in full-time study |
| Projekt: | Identification of molecular targets and mechanisms of resistance in antitumor drugs using cell biology and proteomics methods |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Souhrn: | 2 places in full-time study |
| Projekt: | Genetic and epigenetic biomarkers of cancer diseases |
|---|---|
| Vedoucí: | Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 3 |
| Určeno pro: | Doktorské studium |
| Souhrn: | 3 places in full-time study |
| Projekt: | Identification of proteomic biomarkers in exhaled breath condensate in patients with systemic or pulmonary disease |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Souhrn: | Ph.D. topic is focused on the identification of biomarkers of lung diseases by means of a non-invasive collection of exhaled breath condensate. The project will monitor the presence of proteins in exhaled air in various diseases such as asthma, cystic fibrosis, lung tumors, or some infectious diseases, as well as quantitative changes of these proteins compared to a healthy population. Changes in these potential biomarkers with respect to therapeutic response and disease progression will be evaluated and validated. |
| Projekt: | Identification of molecular targets of anticancer therapy applying cell biology and proteomics tools |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Souhrn: | Selected, highly active derivatives of triterpenes, chelators and nucleosides will be studied with a view to identify the mechanisms of their antitumor effects. Advanced methods of cell biology, proteomics and genomics such as affinity purification of protein targets, CETSA and others will be used for their study. The identified targets will be validated in relation to their clinical relevance in anticancer therapy. |
| Projekt: | Drug resistance mechanisms in cancer |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Souhrn: | Mechanisms of tumor cell resistance to newly developed and existing nucleoside analog cytostatics will be studied. These drugs are used in most anti-cancer therapy protocols and the emergence of drug resistance is a major problem in the treatment of cancer patients. Resistant cell lines prepared in the past will be studied to identify the key mechanisms of resistance, which will be carried out by their detailed characterization using cell biology, but also proteomics and molecular genetics. The significance of the identified changes will be further verified on clinical material and will be applied in the development of new anticancer drugs from this class. |
| Projekt: | Research and development of agents for cancer, neurodegenerative and infectious diseases |
|---|---|
| Vedoucí: | De Sanctis Juan Bautista Ph.D., Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D., Urban Milan Ph.D., Das Viswanath M.Sc., Ph.D. |
| K dispozici: | 5 |
| Určeno pro: | Doktorské studium |
| Projekt: | Genetic and epigenetic biomarkers in health and disease |
|---|---|
| Vedoucí: | Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D., Drábek Jiří Ph.D., Koudeláková Vladimíra Ph.D. |
| K dispozici: | 5 |
| Určeno pro: | Doktorské studium |
| Projekt: | Identification of molecular targets and resistance mechanisms of anticancer drugs by cell biology and proteomics methods |
|---|---|
| Vedoucí: | Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Projekt: | Identification of proteomic biomarkers in exhaled breath condensate patients with systemic or pulmonary disease |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Projekt: | Identification of proteomic biomarkers in proximal fluids and tissues |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |
| Projekt: | Innovative approaches to protein interaction modifiers |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D., Václavková Jana M.Sc. |
| K dispozici: | 1 |
| Určeno pro: | Doktorské studium |
| Projekt: | Utilization of the space of unprecedented covalent inhibitors |
|---|---|
| Vedoucí: | Džubák Petr M.D., Ph.D. |
| K dispozici: | 1 |
| Určeno pro: | Doktorské studium |
| Projekt: | Anticancer drugs targeting nucleic acid metabolism |
|---|---|
| Vedoucí: | Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D. |
| K dispozici: | 2 |
| Určeno pro: | Doktorské studium |